Skip to main content

Atossa Therapeutics, Inc 10-Q for FY2026 Q3

Atossa Therapeutics, Inc. (ATOS)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Atossa Therapeutics, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$5.64M
compared with a net loss of $8.69M a year earlier
Diluted EPS
-$0.56
compared with -$1.01 a year earlier